Drug trial aims to stop Cancer's return after surgery
NCT ID NCT02296684
Summary
This study tested whether adding the immunotherapy drug pembrolizumab (MK-3475) to standard surgery could better control advanced head and neck cancer. It involved 67 high-risk patients with stage III or IV cancer that could be surgically removed. Researchers aimed to see if the drug given before and after surgery could reduce the chances of the cancer coming back locally or spreading to other parts of the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.